anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Soft tissue sarcomas (STS) are a heterogeneous group of benign and malignant tumors of various supportive tissues arising from the mesoderm. There are 56 known subtypes classified by the tissue of origin. Soft tissue sarcomas account for 1% of all human malignancies. These tumors share a common mesenchymal origin with the vasculature. Many of the signaling pathways involved in angiogenesis also drive sarcoma tumor cell growth. Autocrine and paracrine vascular endothelial growth factor (VEGF) - and platelet-derived growth factor (PDGF)-mediated growth plays a role in the pathogenesis of several sarcoma subtypes1. Despite promising preclinical data supporting a role for angiogenesis inhibition in sarcoma, relatively few clinical trials have evaluated antiangiogenic therapy in sarcoma.

Most of the studies for the use of anti-angiogenic drugs have been taken from phase I trials of refractory solid tumors showing a lack of response in sarcomas. This may be due to an inadequate dose, wrong sequence of the treatment or lack of studies with combination treatments. Given the heterogeneity of sarcomas there may be a benefit in certain subgroups that can easily be missed. A recent clinical trial has shown improved cytotoxic cell kill and response rates by epigenetically modifying the tumor environment prior to chemotherapy. It is believed that the efficacy of angiogenesis inhibitors has been shown to be greatly improved when they are combined with other anticancer drugs.

Tumor metastasis is highly dependent on angiogenesis progressing through a metastatic cascade that includes primary tumor growth, modification of tumor cell growth and behavior and formation of new blood vessels. This angiogenic switch is believed to be the result of changes in the balance of angiogenesis stimulators, inhibitors and modulators present at the site of the tumor growth. These changes are due to both genetic alterations involving RAS, RAF, MYC, SRC, EGFR and HER-2 and tumor suppressor genes and epigenetic circumstances such as hypoxia, inflammation or hormonal stimulation. It is clear that vascular endothelial growth factor (VEGF) has emerged as the key stimulatory molecule for promoting angiogenesis in a variety of human malignancies. Other pro-angiogenic factors can be induced or amplified in the presence of hypoxia hypoglycemia, inflammatory cytokines and altered cell-cell contact. Thus it would be of interest to combine epigenetic modifiers like Valproic acid, a histone deacetylase inhibitor, with Bevacizumab, an anti-angiogenic agent against VEGF and standard chemotherapy (Gemcitabine /docetaxel) to better modulate the cytotoxic effects against sarcomas.
Patients in the intervention group will receive peppermint oil aromatherapy as primary treatment for postoperative nausea. Pharmacological therapy with anti-nausea drug therapies will be available as needed. All other aspects of medical, surgical and nursing care will be standard practice for pre and post-operative care related to the bariatric surgical patient. Patients in the intervention group will be assessed every 4 hours and as needed for nausea. Post-intervention, the patient will be re-assessed for level of nausea after one hour. In the event the patient refuses peppermint oil aromatherapy and requests anti-emetic drug therapies, they are able to do so.
The invention belongs to the technical field of healthcare pillows, and discloses a medicine pillow core for treating a headache. The medicine pillow core is prepared from the following raw materials: 80-120 parts of dry chrysanthemum, 30-50 parts of ligusticum wallichii, 15-25 parts of cortex moutan and 15-25 parts of radix angelicae dahuricae. The raw materials are mixed evenly according to the parts by weight, and then are packed into the pillow core in preparation; and the pillow core can be used after being sleeved with a pillow sleeve. The filling medicine in the healthcare pillow core disclosed by the invention is prepared by scientific combination of four carefully selected traditional Chinese medicines by traditional Chinese medical experts through clinical experience for many years. According to the pillow core disclosed by the invention, when people sleep, medicines slowly volatilize due to heat temperature, act on the heads, and play a healthcare role on human health in a sleep. The medicine pillow core disclosed by the invention has the efficacies of activating blood circulation, promoting qi circulation, clearing heat, cooling blood, removing wind to relieve exogenous syndrome and promoting tissue regeneration and relieving pain, and has a significant curative effect on a stubborn headache after being used for a long period of time.
The invention discloses a synthesis method of nanoparticles for treating ankylosing spondylitis. The main steps include 1) preparation of PEG water solution; 2) preparing a PLGA organic solution; 3) IL-10@ MicroRNA-125a nanoparticles were synthesized by thin film hydration. Central to the pathogenesis of ankylosing spondylitis is an imbalance of effector and regulatory T cells (Tregs). Wherein the MicroRNA-125a can regulate Treg cells, and the Tregs play a key role in stabilizing immune homeostasis by inhibiting pathogenic autoreactive immune cells. Interleukin-10 (IL-10) is a multi-cellular, multifunctional cytokine that regulates cell growth and differentiation, participates in inflammatory and immune responses, and is currently recognized as an inflammatory and immunosuppressive factor. PLGA-PEG is nontoxic, has good biocompatibility and good encapsulation and film forming performance.
Parent-Web (PW) is internet delivered parent education that is created and developed by researchers at Karolinska Institute's Department of Clinical Neuroscience, namely Kajsa Lönn-Rhodin, Martin Forster, and Pia Enebrink. An effectiveness trial of the universal edition of the Parent Web is made possible through a research collaboration with Pia Enebrink. PW is derived from social learning and coercion theory. PW aims to support parenting practices and parent-child interactions encourage prosocial behaviour and emotion regulation, reduce coercive parenting, improve communication, problem solving, and warmth within families. PW has a universal and selective edition. Universal PW has 5 basic modules (1 module per week, 6-8 weeks) and bonus modules. Basic modules contain information, exercises, and videos of actors showing parenting practices. A family guide supports PW participants through PW modules. This study will test the effects of universal PW with a general population derived sample of parents living in Region Stockholm. All PW trial participants are parents to at least one adolescent child who is aged 11-13 years old.
OBJECTIVE: To investigate efficacy and prognostic factors in the treatment of adult newly-diagnosed acute myeloid leukemia (AML) with or without allogeneic hematopoietic stem cell transplantation (Allo-HSCT).
METHODS: We retrospectively analyzed 668 patients with newly-diagnosed AML (non-M3 type) in the Department of Hematology at Shanghai Changhai Hospital from January 2012 to December 2021. Based on different induction chemotherapy regimens, patients were categorized into an IA (idarubicin, IDA + cytarabine, Ara-C) (3 + 7, regimen) group (n = 303) and a DA (daunorubicin, DNR + cytarabine, Ara-C) (3 + 7, regimen) group (n = 365) with or without allo-HSCT. Minimal residual disease (MRD), complete response (CR), overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse effects (AE) were analyzed and compared. Characteristics significantly associated with overall or progression-free survival (OS or PFS) upon univariate analysis were subsequently included in a Cox proportional hazard model.
RESULTS: This study used data from 668 AML patients. After induction therapy, the CR rate in the IA group was 70.63% and ORR was 79.87%, which were significantly higher than those in the DA group (with a CR rate of 56.99% and an ORR of 70.14%) (P = 0.0002 and P = 0.0035, respectively). There were no significant differences in drug safety between the two chemotherapy regimens used in IA and DA (P > 0.05). The recurrence rate was lower in patients with an MRD < 0.001 than in patients with an MRD ≥ 0.001. A continuous negative MRD during the period is significant because it is associated with prolonged OS and PFS of AML patients. Data from 100 patients in the two groups who underwent allo-HSCT were analyzed using univariate analysis and the Cox proportional hazards model. From the multivariate analysis, MRD was found to be the only independent predictor of OS (P = 0.042; HR 1; 95%CI 0.00-0.76).
CONCLUSION: In the treatment of adult AML patients, IA regimen is associated with a high CR rate and ORR rate and does not increase treatment-related toxicity. IA regimen prolongs OS and PFS in AML patients and reduces the likelihood of leukemia cells' subsequent infiltration into the central nervous system. There is a high correlation between the level of MRD after treatment and the patient's bone marrow recurrence. To obtain superior treatment effects for patients undergoing allo-HSCT, the MRD should be reduced to less than 0.001 before pretreatment. A negative MRD before allo-HSCT can prolong OS in patients with AML. We examined the clinical characteristics and outcomes of AML patients in China, finding novel information on prognostic factors and primary treatment of AML that may be applicable in routine clinical practice.
PURPOSE: An extract fraction of Hovenia dulcis Thunb. branches and a polysaccharide fraction separated from the same exhibiting a reducing effect on hepatotoxicity, hangover and fatigue are provided Therefore, they are useful as prophylactic and therapeutic agents for the prevention and treatment of various liver diseases. CONSTITUTION: One to four year old Hovenia dulcis Thunb. branches are extracted in water or lower alcohol, the extract is passed though an ion exchange column with a sodium chloride solution as an eluent to produce a polymeric polysaccharide having a molecular weight of 20,000D or more. The Hovenia dulcis Thunb. is Hovenia dulcis var. Koreana Nakai, Hovenia dulcis var. tomentella Makino, Hovenia dulcis var. latifolia Nakai.
The Investigators propose a pilot study which utilizes bpMRI in conjunction with PSA in the early detection of clinically significant prostate cancer in a high-risk group. Our study would focus on these high-risk subjects between the ages of 40-55 with a normal PSA ranging from ≥1.0 to \<2.5 ng/mL. bpMRI would be obtained in this group of subjects. If any suspicious lesions are found, the recommendation is to undergo MRI/US fusion biopsy. Subjects with negative bpMRI will be followed every year with serum PSA. Subjects with a positive bpMRI will have a prostate fusion and systematic biopsy performed. Those with a benign biopsy will be followed every year with serum PSA. Those who have a biopsy positive for cancer will be managed and followed according to the standard of care. All subjects will be followed for 5 years. Our hypothesis is that bpMRI in conjunction with above average PSA in a high-risk group will increase detection of clinically relevant prostate cancer and provide a useful addition to PSA screening.
Central vision loss (CVL) is a major form of low vision that remains inadequately managed worldwide. This study evaluated the clinical efficacy of a novel head-mounted device (HMD), Onyx, designed to enhance visual function and vision-related quality of life for CVL patients. It employs a projection system that enables patients to leverage their residual peripheral vision for environmental awareness. It also integrates artificial intelligence to augment the automatic recognition of text, faces, and objects. In this single-center, prospective cohort study, 41 binocularly low vision patients with CVL were instructed to use Onyx for 4 to 6 h daily over a one-month period. Various metrics were assessed, including near and distance visual acuity (VA), recognition abilities for faces and objects, and the low vision quality-of-life (LVQOL) questionnaire scores, at the start and end of the study. The results showed significant improvements in near VA for 60.98% of the participants, distance VA for 80.49%, and recognition ability for 90.24%. 68.29% of the participants showed significant improvements in the LVQOL scores. Improvement in recognition ability was negatively correlated with baseline recognition ability. Additionally, improvement in the LVQOL scores was correlated with age and the baseline LVQOL score. Overall, the study found that the novel HMD significantly improved visual function and vision-related quality of life for low vision patients with CVL, highlighting the potential benefits and the need for further evaluation of such devices.
Patients are enrolled in balanced numbers based on gender and stratified by viral load (less than or equal to 10,000, 10,000 to 100,000, or more than 100,000 copies/ml). Prior to therapy, a peer-based patient education intervention is presented. Patients receive a combination of IDV, RTV, enteric-coated ddI, and d4T. Responses to this multi-agent antiretroviral drug regimen are explored based on sex differences. A pharmacokinetic sub-study, balanced so that half of patients are male and half are female, is performed on IDV and RTV for 20 to 25 of the patients. About 20 females are examined for study-drug effects on gonadotropic hormone levels.
The present invention relates to a recipe and a preparation technology for Changning gel. The major component of the recipe includes cooked rhubarb, yellow-corktree bark, gall, common bletilla pseudobulb, phosphonic acid, hydroxypropyl methylcellulose, etc. The preparation technology prepares the Changning gel by that an alcohol extraction concentrated solution and a water extraction concentrated solution are combined, and then hypromellose is added. The present invention can be directly taken via rectum. The medicine can directly act on focuses and can display the local action. The medicine has excellent protect action on tunica mucosa recti and has long residence time on the infected region. The present invention has the functions of clearing heat and drying damp and stopping bleeding by astringency and has the advantages of high absorption speed of tunica mucosa recti, no liver first pass effect, easy use, no toxic or side effect and stable and reliable therapeutic effect.
To the investigators knowledge, there is no treatment trial for prazosin use in patients with bulimia nervosa struggling with nightmares, looking at either objective or subjective measures. The investigators plan to probe the effectiveness of prazosin in bulimic patients experiencing nightmares due to PTSD using both subjective and objective measures in order to improve future clinical care. The effects of prazosin on decreasing nightmares and bulimic symptoms on subjective scales and effects on sleep architecture using objective polysomnogram (PSG) measurements will help inform targeted psychopharmacologic and psychotherapeutic strategies to improve clinical care of bulimic patients struggling with distressing dreams secondary to PTSD. This study will be performed in two phases. Phase A will involve eight participants who will be tested using subjective scales (mentioned below). If Phase A data analysis leads to detection of a signal of efficacy 2 more participants will be recruited to participate in phase B of this trial using objective polysomnogram measurements. The results from this project will aid in establishing a fully powered clinical trial for treatment of nightmares in bulimic patients and improve outcomes in this high risk population.
CBOT consists of 40 cycles of olfactory stimulation and OFC training tasks, lasting \~45 minutes, once daily over 3 months. Treatment-as-usual (TAU) is standard dosing of buprenorphine (BUP) to a median dose of 24 mg (range 16-32 mg).
Asthma, the leading chronic disorder in childhood, is the number one cause of pediatric emergency department (ED) visits in young children and is responsible for a substantial impact on healthcare costs. The ED is often the point of contact for low-income children and many families view the ED as their primary source of asthma care. Poor and minority children have the highest asthma morbidity, are the least likely to receive adequate preventive therapy or specialty care and more frequently exposed to environmental triggers than non-poor children. However, prior studies, including our pilot, indicate that children with frequent asthma ED visits will attend a one-time ED-based follow-up clinic for an asthma "check-up" and education. The goal of this randomized controlled trial is to test the efficacy of a multifaceted, ED + primary care provider (PCP) and home-based intervention, Asthma Express (AEx), for children with \> 2 asthma ED visits or 1 hospitalization/year that provides tailored guideline based asthma care. Allergy and cotinine biomarkers, collected during the ED visit, are used to target the home environmental control component of the intervention. The AEx intervention (n=132) will be compared to an attention control (CON) group (n=132) for the specific aims: (1) to reduce asthma morbidity (increase symptom free days and nights) and decrease ED visits and hospitalizations and increase asthma control and caregiver quality of life, (2) to improve the use of appropriate preventive anti-inflammatory medication based on child pharmacy refill records and (3) to compare the economic cost and effects of this intervention. Children aged 3-12 years with \> 2 asthma ED visits or 1 hospitalization within the past 12 months and a current ED visit for asthma will be recruited from the Johns Hopkins Pediatric-ED and followed for 12 months. Symptom frequency, health care utilization, caregiver quality of life and cotinine measures will be collected at baseline, 6 and 12 months and pharmacy data collected at baseline and 12 months. Data analysis includes initial cross tabulations of health outcomes by group (AEx vs. CON) and multivariate generalized linear regression models to study the effects of the AEx treatment on mean symptom free days/nights, repeat ED visits, hospitalizations and caregiver quality of life scores and anti-inflammatory medication refills. Mean total costs of ED, PCP visits, hospital days and medication costs will be compared between groups (AEx and CON) for the economic analysis. The AEx model is designed to be accessible, guideline-based, easily replicated and incorporated into ED care. If successful, this study will fill critical gaps in the ED transition to preventive care asthma interventional research.
A relaxation formulation structured to induce a deep state of relaxation in a person comprises amounts of tryptophan, melatonin, vitamin B3, and vitamin B6. Another relaxation formulation also includes an amount of tyrosine, and yet another formulation includes an amount of vitamin B12. At least one embodiment of a relaxation formula comprises a physiologically effective amount of gamma-aminobutyric acid ("GABA"). A delivery system is provided to facilitate administration of the relaxation formulation to a person. The delivery system may include an edible high carbohydrate matrix, such as a chocolate brownie. Alternatively, the delivery system may comprise an inert vaporizable compound to allow the components of the relaxation formulation to be inhaled directly into the lungs of a person. Other delivery systems include an aqueous sublingual spray and a beverage.
PROBLEM TO BE SOLVED: To provide a composition containing flavin-adenine dinucleotide or a salt thereof stabilized at a high level even in an aqueous solution. SOLUTION: The stability of the flavin-adenine dinucleotide or a salt thereof to the light is improved by adding 0.01-100,000 pts.wt. xanthines (caffeine, theophylline or the like) based on 1 pts.wt. flavin-adenine dinucleotide or salt thereof. The composition is useful as an aqueous composition, e.g. a topically applied composition such as an eye drop, and a composition applied to the mucous membrane.
BACKGROUND: Excessive body weight and obesity elevate the risk of chronic non-communicable diseases. The judicious application of the gut microbiome, encompassing both microorganisms and their derived compounds, holds considerable promise in the treatment of obesity.
RESULTS: In this study, we showed that a cocktail of gut microbiota-derived metabolites, comprising indole 3-propionic acid (IPA), sodium butyrate (SB) and valeric acid (VA), alleviated various symptoms of obesity in both male and female mice subjected to a high-fat diet (HFD). The 16S ribosomal RNA (rRNA) sequencing revealed that administering the cocktail via oral gavage retained the gut microbiota composition in obese mice. Fecal microbiota transplantation using cocktail-treated mice as donors mitigated the obesity phenotype of HFD-fed mice. Transcriptomic sequencing analysis showed that the cocktail preserved the gene expression profile of hepatic tissues in obese mice, especially up-regulated the expression level of leptin receptor. Gene delivery via in vivo fluid dynamics further validated that the anti-obesity efficacy of the cocktail was dependent on leptin signaling at least partly. The cocktail also inhibited the expression of appetite stimulators in hypothalamus. Together, the metabolite cocktail combated adiposity by retaining the gut microbiota configuration and activating the hepatic leptin signaling pathway.
CONCLUSIONS: Our findings provide a sophisticated regulatory network between the gut microbiome and host, and highlight a cocktail of gut microbiota-derived metabolites, including IPA, SB, and VA, might be a prospective intervention for anti-obesity in a preclinical setting. © 2024 Society of Chemical Industry.
In the experimental group, participants performed the RHK exercises using incrementally resistive elastic tubing. The RHKs targeted shields (Adidas, Curved Kick Shield) held at chest height. Each athlete started with a 2.4 m elastic tubing, one end attached to the ankle and the other to a stable platform, ensuring the tubing's resistance reached 50 N at full kicked extension (Fig.1). After four weeks (12 sessions), resistance increased to 100 N by adding another tubing. Each session comprised three sets of 6 RHKs per leg, at maximum speed, with 30-second intervals between kicks and 3-minute rests between sets. This 8-week, three times weekly, training regimen involved incremental ER training.
The invention discloses a traditional Chinese medicine composition for treating a toothache. The medicinal effective components are prepared from the following raw materials: 20-30 parts of cortex moutan, 20-30 parts of coptis chinensis, 20-30 parts of fructus forsythia, 10-20 parts of scutellaria baicalensis, 10-20 parts of bamboo leaves, 10-20 parts of schizonepeta, 5-15 parts of angelica sinensis and 5-15 parts of spina gleditsiae. The preparation method comprises the following steps: (1) adding 700-800ml of water to traditional Chinese medicines, soaking the traditional Chinese medicines at a room temperature for 30-60 minutes, decocting with a slow fire, removing residues and decocting 150-200ml of liquid medicine after boiling for 10-15 minutes; (2) adding 700-800ml of boiling water to the herb residues, removing the residues and decocting 150-200ml of liquid medicine after boiling for 15-20 minutes; and (3) blending the liquid medicines. The traditional Chinese medicine composition can be warmly taken once a day before meals, and can be taken twice a day in a severe case. The traditional Chinese medicine composition disclosed by the invention has obvious effects of eliminating swelling and alleviating pain on a wind fire toothache, cold and hot toothaches, swelling and aching of gum, gum inflammation and dental pulp inflammation. By the traditional Chinese medicine formula, the immune function of a human body is improved; the traditional Chinese medicine composition is small in toxic or side effect, good in treatment effect and short in treatment course, and ensures that toothache is not easy to recur after being cured.